Price action shows a significant dip from November 2025 highs around $109 and January 2026 peak of $112 to recent lows near $90 in late March 2026, with the current price of $95.27 providing a favorable entry point near support levels after a multi-month pullback, potentially signaling the start of upward momentum on lower volume consolidation. The company's fundamentals are robust, with high ROE of 29.8%, strong gross and net margins over 93% and 24%, reasonable P/E of 16.3, solid revenue growth of 12-14% over 3-5 years, healthy liquidity (current ratio 3.2), and manageable debt (D/E 0.76), indicating underlying strength in the biotechnology sector. Key risks over the 2-12 week horizon include biotech-specific volatility from potential clinical trial updates or regulatory news (none specified), broader market downturns despite low beta of 0.82, and the possibility of further downside if the downtrend resumes below $90. Overall, this is a BUY for a swing trade with estimated 10-15% upside potential back toward $105-110 resistance levels within 2-12 weeks, supported by strong fundamentals and a classic dip-buy setup.

INCY is currently at $95.27, which represents a pullback from its November 2025 peak of $109.28 but remains elevated relative to its August 2025 lows (~$70), suggesting limited near-term upside in a 2-12 week window. The price action over the past 8 weeks shows a clear downtrend with lower highs and lower lows (from $109.28 in mid-November to $94.86 in early April), indicating weakening momentum and a lack of a clear reversal catalyst at current levels. While the fundamentals are solid (P/E of 16.3, ROE of 29.8%, strong margins, and healthy balance sheet with 3.20 current ratio), these don't offset the technical deterioration and the stock's failure to hold above $100 despite multiple attempts since December 2025. For a swing trade targeting 2-12 weeks, the risk/reward is unfavorable—the stock would need to break above $105-109 resistance to generate meaningful upside (10-15%), but the downtrend suggests a higher probability of testing support near $90 first, making this an inferior entry point compared to waiting for either a confirmed reversal pattern or a deeper pullback to $85-88 levels.

Incyte (INCY) is currently presenting a compelling swing trade entry point as the price has stabilized around the $90-$95 range after a healthy correction from its 52-week highs near $112. The stock's fundamental health is exceptionally strong for a biotech firm, boasting a high ROE of 29.8%, a low P/E ratio of 16.3, and an impressive gross margin of 93.5%, which provides a solid floor for the valuation. Key risks over the 2-12 week horizon include potential clinical trial data volatility and broader sector weakness, but the current ratio of 3.20 suggests the company is well-capitalized to handle short-term headwinds. Given the recent bounce off the $90 support level and the historical upward momentum seen in late 2025, I anticipate a recovery toward the $105-$108 resistance zone, representing an estimated upside potential of approximately 10-13%.

Price action: INCY has pulled back from its January highs (~$112) into a base around $90–$100 and has shown a clear short-term bounce the last two weekly closes (from ~90.3 to ~94.9). That puts the stock near a logical swing-entry zone (buy on the early recovery off support) with nearby resistance in the $105–110 area which is a reasonable short-term target. Fundamentals: the company looks healthy for a biotech/large-cap pharma-adjacent name — strong gross margin (93.5%), solid net margin (24.7%), high ROE (29.8%), healthy liquidity (current ratio 3.2), moderate leverage (D/E 0.76) and a reasonable P/E (16.3) given mid-teens revenue growth; these reduce the probability of a fundamental shock versus smaller biotech peers. Key risks (2–12 week horizon): biotech-specific headline risk (trial/FDA/partnership news) or an earnings/guidance miss could trigger sharp moves; a break back below the $90 support would invalidate the swing setup and open the path to the $80s; broader market/sector weakness could also blunt upside. Final verdict & upside: this is a tradable short-term setup — BUY for a 2–12 week swing with a target zone around $105–$110 (~10–16% upside) and a tight stop (e.g., below $88–90) to control risk; if you need a larger margin of safety or wish to avoid headline risk, SKIP instead.